| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
From the Division of Carcinogenesis and
Differentiation,*
German Cancer Research Center (Deutsches
Krebsforschungszentrum), Heidelberg, Germany; and the Department of
Oral Biology and Pathology,
School of Dental
Medicine, State University of New York, Stony Brook, New York
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
We have previously developed an in vitro cell transformation system of human skin keratinocytes and characterized the genetic and phenotypic alterations associated with the subsequent stages of carcinogenesis to squamous cell carcinomas (SCCs).4 In parallel, we have studied the tissue-related changes occurring with tumorigenesis and malignant progression and have begun to characterize the accompanying alterations induced by transformed epithelia in the neighboring connective tissue, using a matrix-inserted surface transplantation assay.5,6 In these studies, we have demonstrated the critical role of the tissue microenvironment in controlling and enhancing distinct stages in skin carcinogenesis both by intraepithelial7 and epithelial-mesenchymal interactions.5,6,8 In vitro transformation of human cells requires, as a first step, the loss of cell senescence and acquisition of immortality, leading to permanently growing but nontumorigenic cell populations.9-11 This immortalization process is frequently induced by transfection or infection with oncogenic viruses such as simian virus 40 or human papilloma virus-16, -18, or -31.12-14 Tumorigenic conversion of these immortalized cells can then be induced by chemical and physical carcinogens or by specific oncogenes.15-18 In addition, long-term passage of some of these virally immortalized cells leads to spontaneous progression to a tumorigenic phenotype, suggesting a certain degree of genetic instability in these cells.19-24
We have established a multistage skin carcinogenesis model system based on the spontaneously immortalized human keratinocyte line HaCaT.4,25 This cell line does not harbor any viral sequences that might add to genetic instability and thus has maintained its nontumorigenic phenotype for extended culture passages.26 Moreover, HaCaT cells closely resemble normal human keratinocytes in their growth and differentiation potential25,27-30 and have thus become a frequently used model system to study keratinocyte biology and transformation. Immortalization of HaCaT cells was most likely a consequence of UV-type mutations in both alleles of the p53 tumor suppressor gene31 similar to those found in a high percentage of skin carcinomas and premalignant lesions.32 In addition, HaCaT cells show a loss of chromosomes 3p, 4p, and 9p, areas in which senescence genes have been identified or postulated.33 Despite these genetic alterations, HaCaT cells retain a stable chromosome content and remain nontumorigenic throughout 320 passages.26 Because of their genetic make-up and primarily maintained phenotypic normality, they are considered to represent a very early stage in skin tumorigenesis.4 Their tumorigenic conversion was achieved by transfection with the mutated val-12 Harvey-ras oncogene34 but also by growth under elevated temperature (sunburn conditions)35 or extremely stressful culture conditions such as repeated single cell cloning36 or adaptation to autotrophy.37 In epithelial skin tumors, an activated ras oncogene has been detected in squamous and basal cell carcinomas, suggesting its causal role at least in a subset of epithelial skin tumors.38,39 Tumorigenic conversion of the HaCaT cells resulted in clones growing as epidermoid cysts (benign tumors) after subcutaneous injection.34 Additional loss of copies of chromosome 15 in the ras-transfected HaCaT cells was correlated with malignant tumor cells, forming well-differentiated SCCs in nude mice.33,40 Here we report that further progression of the malignant HaCaT-ras clones to even more aggressive and eventually metastatic phenotypes was not observed after extended passaging in vitro or after culture stress such as repeated single cell cloning. In contrast, their late passage cells exhibited reduced tumorigenicity when injected subcutaneously into nude mice, resulting in diminished tumor growth rates. On the other hand, cells recultured from established heterotransplants showed an increased malignant potential when reinjected into animals, indicating that the in vivo microenvironment exerted a selective pressure and favored malignant progression. We have studied this phenomenon in detail and observed a stepwise tumor progression to highly malignant and metastasizing tumor cell lines obtained through sequential in vivo passages. Characterization of the accompanying genetic and phenotypic changes strongly indicates both clonal selection and further genetic alterations as causal mechanisms for the development of advanced tumor stages. This tumor progression, shown to be stably maintained in recultured tumor cells, is associated with distinct genetic alterations and is phenotypically characterized by an altered growth regulation.41
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Cell lines used in this study are the benign HaCaT-ras clone A-5,
the malignant HaCaT-ras clones II-3 and II-4,34
as well as
the benign tumorigenic HaCaT line HaCaTp36
and the
malignant line HaCaT40°35
(Figure 1)
. The latter two cell lines had been
converted to tumorigenicity by culture stress. The stress was exerted
either by repeated single-cell cloning (HaCaTp) or by continued growth
(>10 passages) at 40°C instead of 37°C (HaCaT40°). Under both
stress conditions HaCaT cells were converted to tumorigenicity. The
tumors formed were either noninvasive, slowly growing benign cysts
HaCaTp36
or locally invasive SCCs
HaCaT40°.35
The following cell lines were established
after in vivo passage by recultivation of subcutaneously
transplanted tumors: HaCaTpT, HaCaT40°RT, II-3RT, II-4RT, A-5RT1, and
A-5RT3 (Figure 1)
.
|
Cell lines were cultivated in 4x modified Eagle’s medium with 5% fetal calf serum (FCS) following routine protocols.25 Both benign and malignant HaCaT clones were serially passaged at a split ratio of 1:5 to 1:10 and tested for tumorigenicity at different passage levels. The cell lines A-5 and II-4 were cloned by ring isolation and clonal populations were again tested for tumorigenicity. For recultivation of tumor cells, subcutaneous tumors were surgically removed from the nude mouse, separated from stroma and necrotic areas, and proliferative tumor margins were minced into 1-mm3 pieces. These tumor fragments were transferred to 10-cm tissue culture plates containing 6 x 106 lethally irradiated (70 Gy) human fibroblast feeder cells in standard media. When islands of tumor cells had formed (after 5 to 10 days) the pieces of tumor tissue were removed by aspiration and the cells were further cultivated according to standard protocols.25 Cells were routinely tested for mycoplasma contamination by standard procedures42 and always found to be negative. Their origin from transfected HaCaT-ras cells (containing the neo-resistance gene34 ) as well as the absence of contaminating mouse cells were proved by the resistance of the recultivated cells to G418 (400 µg/ml) treatment. For HaCaT40° and HaCaTp cells elimination of mouse cell contamination was done as described.35
Growth Curves and Colony-Forming Efficacy
Growth curves were recorded from cells seeded at a density of 4 x 103 cells/cm2 in 4x modified Eagle’s medium with 5% FCS by daily counting of the cells in three independent cultures with an electronic counter (Casy, Schaerfe System, Reutlingen Germany). For determination of colony-forming efficacy, cells were plated at a density of 100 cells/6-cm dish in 4x modified Eagle’s medium containing 1% FCS. After 24 hours, allowing for cell attachment, medium was shifted to 5% FCS or no FCS, respectively. After 10 days the medium was removed, cells were fixed in 3.7% formaldehyde, stained with Mayer’s hematoxylin, and colonies were counted. Colony-forming efficacy was calculated as the ratio of colonies to the number of cells seeded. The colony-forming efficacy of A-5 cells was arbitrarily set to 100%.
Cytogenetic Analysis
Semiconfluent cultures were harvested by trypsinizing with 0.1% trypsin/ethylenediaminetetraacetic acid in phosphate-buffered saline without Ca2+ and Mg2+ containing 4 mg/ml colcemid, centrifuged, and the cell pellet resuspended in hypotonic solution of 70 mmol/L KCl. After incubation at 37°C for 15 to 25 minutes cells were fixed by three changes of methanol/acetic acid 3:1 and spread on glass slides. G-banding was performed after the slides had been aged for several days as described.43 To analyze numerical chromosome alteration, at least 50 metaphases were counted and 25 karyotypes were arranged and analyzed for structural changes.
Tumorigenicity and Metastasis Assays
Tumor formation was assayed after subcutaneous injection of 5 x 106 and 1 x 105 cells in 100 µl of culture medium into the interscapular region of 4- to 6-week-old athymic nude (Swiss nu/nu) mice and tumor size was measured in two axes throughout an observation period of 6 months. The tumor volume was calculated following published procedures.40 The metastatic potential of tumor cells was assayed using two separate transplantation systems. Experimental metastasis was assayed by injecting 1 x 106 cells into the tail vein of athymic nude mice and lung colony formation was monitored for a period of 18 weeks.
Spontaneous metastasis from tumor cells grafted as skin-like surface transplants was determined after the transplantation of organotypic cultures as described previously.7 Briefly 7-day-old organotypic co-cultures of tumor cells were trimmed using a surgical punch (1.4 cm in diameter) and transplanted onto the back muscle fascia of nude mice. Animals were sacrificed at 9 weeks after transplantation, and grafts as well as regional lymph nodes were dissected and prepared for histology.
Successive in vivo passages of tumor cells without intermittent in vitro growth were performed by subcutaneous transplantation of tumor fragments from the previous in vivo passage. Tumors were surgically removed, separated of stroma and necrotic areas, and 0.5 mm3 pieces of the proliferative tumor margins were subcutaneously transplanted via skin incision. Tumor growth was observed for up to 6 months and monitored by weekly measurements of two tumor diameters.
Southern Blot Analysis
Genomic DNA of cultured tumor cells was isolated by the sodium dodecyl sulfate lysis procedure,44 and 10 mg of DNA were digested overnight at 37°C with the restriction endonucleases BamHI and EcoRI, respectively. Hybridization conditions, electrophoresis, and autoradiographic procedures were as described previously.45
Immunoprecipitation
Cellular proteins were extracted from 107 trypsinized cells and the ras proteins immunoprecipitated as described previously.10 Samples were electrophoresed on 7.5 to 17.5% sodium dodecyl sulfate-polyacrylamide gels and electroblotted in buffers to an Immobilon P membrane (Millipore, Bedford, MA, USA) according to established procedures.46 Antibody reactions and visualization of the immunoreactive proteins were performed as described previously.10 The antibody used was a pan-reactive H-ras antibody v-H-ras Ab-1-A clone Y13-259 (Oncogene Science, Boston, MA, USA).
Oligonucleotide Primers and Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
Sense and antisense primers for granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) were synthesized according to the sequences extracted from GenBank and used as described previously.41 All oligonucleotide primer pairs spanned intron-exon splice sites ensuring that PCR products generated from any DNA present in the RNA preparations could be clearly distinguished from those generated in the RT-PCR reactions. RT-PCR was performed as described41 using the Perkin-Elmer (Branchburg, NJ) Geneamp RT-PCR kit. The identity of the PCR amplification products was confirmed by size and restriction digest with two restriction enzymes.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Tumor Progression of the Benign HaCaT-ras Clone A-5 by in Vivo Passaging
Early-passage (p16) benign HaCaT-ras A-5 cells were injected into
eight nude mice. After forming an initial nodule, four out of eight
tumors regressed within the first 50 days after injection or remained
the same size (Figure 2a)
. Two tumors
persisted as small stationary nodules, consisting of a rim of squamous
epithelia surrounding a keratinized central part (Figure 3a)
, and two tumors progressively
enlarged after a latency period of 40 and 60 days, respectively (Figure 2a)
. Vital tumor segments of one of these tumors (Figure 2a
, arrowhead)
were removed and processed in vitro to establish the
recultivated tumor cell line A-5RT1. In addition, tumor fragments were
subcutaneously transplanted into nude mice, resulting again in
different tumor types (Figure 2b)
. Although two out of eight
transplants had disappeared completely after 4 weeks, four tumors
showed a faster growth than the original tumor, reaching a size of 0.8
to 1.2 cm3
after 30 to 40 days. The remaining two
nodules grew slowly and finally remained stationary for several months.
Vital segments of one of these latter tumors (Figure 2b
, arrow), which
exhibited a late growth enhancement, were again transplanted
subcutaneously. Despite its originally slow growth, retransplantation
of this tumor resulted in a homogeneous series of very fast growing
tumors reaching a tumor volume of 0.6 to 1.5 cm3
after 20 to 30 days (Figure 2c)
. One tumor of this third
transplantation was again dissected and recultured to establish the
recultivated tumor cell line A-5RT3 (Figure 2c
, arrowhead).
|
|
, the faster growing variants were still
well-differentiated, although invasive, tumors (Figure 3b)
. After a
further in vivo passage the resulting SCCs exhibited reduced
differentiation accompanied by increased cell and nuclear atypia
(Figure 3c)
. The rapidly growing tumors resulting from the third
in vivo passage (see Figure 2c
) were highly disorganized,
infiltrating, and poorly differentiated SCCs with cellular atypia and
large central necroses (Figure 3d)
. In a second set of experiments with a comparable passage of A-5 cells (p17) the tumorigenic progression by in vivo passage was shown to be highly reproducible resulting in a comparable yield of benign and malignant heterotransplants (data not shown).
The Recultivated Tumor Cells Maintain the Enhanced Malignant Phenotype
On subcutaneous reinjection of the newly established, recultivated
tumor cell lines A-5RT1 and A-5RT3 we demonstrated that the in
vivo growth potential and phenotype of the different steps of
tumor progression were maintained in the tumor-derived cell lines
in vitro. Thus, comparable to the results of the first
heterotransplants, the recultured A-5RT1 cell line (p9) formed
progressively growing, invasive SCCs at three out of eight injection
sites, whereas the remaining five regressed after 2 to 8 weeks (data
not shown). Subcutaneous injection of the cell line obtained after the
third in vivo passage as tumor fragments (A-5RT3 passage 8)
led to extremely rapidly growing tumors in all animals (Figure 2d)
.
Thus, A-5RT1 and A-5RT3 cells show an in vivo growth
behavior comparable to the original tumor cell populations from which
the cell lines were established (compare Figure 2, c and d
). Similarly,
the histology of the resulting heterotransplants exhibited the
phenotype of moderately (A-5RT1) and poorly (A-5RT3) differentiating
SCCs (data not shown for A-5RT1 but compare Figure 3c
), the latter
exhibiting rapid infiltration into the back muscle (Figure 3e)
.
Further confirmation of the enhanced malignancy of the A-5RT1 and
A-5RT3 cells was obtained by the metastatic potential of these cells.
Injection of A-5RT1 and A-5RT3 cells into the tail vein of athymic nude
mice resulted in the establishment of lung colonies for A-5RT1 cells in
two of four animals and for A-5RT3 cells in four of four animals after
10 weeks, respectively. In addition, A-5RT3 transplants of organotypic
cultures grafted onto the dorsal fascia of nude mice7
resulted in spontaneous metastasis of these highly malignant tumor
cells into axillary lymph nodes. Nine weeks after transplantation, all
animals (n = 4) had large tumors at the site of
transplantation, two animals showed two positive lymph nodes, and two
animals had three positive nodes (Figure 3f
, insert). Histological
investigation of the enlarged lymph nodes showed the destruction of
nodal architecture by infiltrating streaks of tumor cells that extended
to the node capsule (Figure 3f
, arrow). Infiltrating tumor cells were
poorly differentiated with high nuclear atypia similar to A5-RT3 cells
(Figure 3e)
.
Tumor Progression Is Associated with Specific Cytogenetic Changes
The reproducibility of this tumor progression under in vivo conditions and the stability of the malignant phenotype of the A-5RT1 and A-5RT3 cells after in vitro passage, raises the question whether the progressed tumor phenotypes were the result of selection of pre-existing tumor cell populations from the parental benign A-5 cell line and/or were the consequence of further genetic alterations induced by the in vivo microenvironment.
To address this question, we examined the chromosomal alterations that
were associated with in vivo tumor progression of the A-5
cell population. To study the population dynamics, we first analyzed
the median chromosome content of the three cell lines. In the benign
A-5 cells, 70% of the metaphases contained 75 to 80 chromosomes with a
mean of 76 chromosomes (Figure 4a)
. Both
the mean and the variation in chromosome content were
clearly reduced in A-5RT1 cells, ranging from 72 to 76 chromosomes in
73% of cells with a mean of 74 chromosomes. The reduction in
chromosome number indicates a selection of a population with fewer
chromosomes. This tendency was most pronounced in the A-5RT3
cells, where 72% of metaphases only exhibited 69 to 72 chromosomes
with a mean of 70 (Figure 4b)
. Thus, with each in vivo
passage and resulting tumor progression, the mean chromosome number was
decreased, indicating a continuous reduction in heterogeneity of the
parental A-5 cell population by selection of subpopulations.
|
1). These data unequivocally
demonstrated: 1) the descent of the advanced tumor lines A-5RT1 and
A-5RT3 from the A-5 cell line as proved by the unaltered maintenance of
the HaCaT and A-5 marker chromosomes M1, M4, M5, M7, M9, and M10; 2)
that the two recultivated tumor cell lines represent subpopulations of
the A-5 cell line because the modified marker chromosome M1*, present
in only 16% of A-5 metaphases, was found in all cells of both
recultivated tumor lines and, because M2, present in two copies in 93%
of A-5 cells, was only detected as a single copy in the recultivated
tumor cell lines; 3) that the recultivated tumor lines had unique
markers (M1RT and M2RT) not discovered in A-5 cells; and finally 4)
that the second recultivated tumor marker M2RT had duplicated during
the progression from A-5RT1 to A-5RT3 (Table 1)
.
|
H-ras Oncogene Amplification and Overexpression during Tumor Progression
Transfection of the activated H-ras gene into immortal HaCaT cells originally resulted in their tumorigenic conversion, demonstrating a functional role of the H-ras oncogene in the transformation process. We examined the H-ras status in the benign A-5 and malignant A-5RT1 and A-5RT3 cells to determine the potential role of this oncogene during tumor progression as well.
In Southern blot hybridization of BamHI- (not shown) and
EcoRI-digested genomic DNA with a H-ras-specific
probe, the endogenous H-ras proto-oncogene is visible as a
23-kb band (Figure 5a)
. The exogenous
H-ras oncogene gave rise to an additional 13-kb band for A-5
cells and showed a significant (eightfold) increase in intensity for
both A-5RT1 and A-5RT3 cells (Figure 5a)
. The alterations in band
intensity at 13 kb and the additional 6.6-kb band might be the result
of an amplification and novel integration of the oncogene during tumor
progression. Alternatively, this pattern in the recultivated tumor cell
lines may have been caused by selection of a pre-existing but minor
population of A-5 cells during the in vivo progression.
|
. This
increase in H-ras oncogene expression was similarly
demonstrated at the RNA level using RT-PCR with specific primers
discriminating wild-type and Val-12-mutated H-ras (data not
shown). Thus, tumorigenic progression of benign A-5 cells to the
high-grade malignant phenotype seems associated with an amplification
and a relatively strong increase in the mRNA and protein expression of
the integrated (Val-12) H-ras oncogene,
suggesting a role of the oncogene during tumor progression. Tumor Progression through in Vivo Microenvironment Is Not Restricted to ras Transfectants
Acquisition of a more aggressive growth behavior after in
vivo passage of premalignant tumor cells was not restricted to the
ras-transfected HaCaT A-5 cell line. Similarly, two other
ras-transfected HaCaT clones, manifesting a malignant
behavior, exhibited enhanced malignant tumor growth as subcutaneous
heterotransplants after recultivation from excised tumors. Thus, the
HaCaT-ras lines II-3 and II-4, which generate well-differentiated SSCs
after subcutaneous injection in nude mice,34
displayed
significantly faster tumor growth rates than their parental cell lines
when recultivated from subcutaneous tumors (cell lines II-3RT and
II-4RT) and reinjected into nude mice (Figure 6)
.
|
. This in vivo progression of HaCaT clones, which had been
converted into tumorigenicity without the influence of the
H-ras oncogene to an enhanced malignant tumor phenotype, has
been reproducibly observed.35,36 Altered Growth Regulation through Microenvironment-Induced Tumor Progression
The most prominent feature of the heterotransplant-derived cell lines was their enhanced growth potential in vivo as manifested by the accelerated enlargement of tumors. This was indicative of an improved adaptation of cells to growth in the subcutaneous environment and was particularly obvious with the metastatic A-5RT3 cells, which exhibited a comparable graft-take and tumor growth rate when the number of injected cells varied from 5 x 106 to 1 x 105 cells. Tumor growth in 100% of animals was indeed still observed after subcutaneous injection of as little as 1 x 105 cells (data not shown).
This growth potential indicated an improved autocrine growth regulation
and independence of environmental growth control mechanisms.
Investigation of the growth-factor expression profile of the highly
malignant tumor cell lines established after in vivo passage
revealed a common characteristic. Both HaCaT tumor cell lines HaCaTpT
and HaCaT40°RT, as well as the HaCaT-ras tumor cell lines II-4RT,
A-5RT1, and A-5RT3, exhibited a de novo expression of the
hematopoietic growth factors G-CSF and GM-CSF (Figure 7)
(protein expression data as determined
by enzyme-linked immunosorbent assay not shown).41
Because
all HaCaT cell variants expressed the cognate receptors for G-CSF and
GM-CSF,41
the novel expression of both factors in these
highly malignant tumor cells represents a shift from
microenvironmentally determined paracrine to an autocrine growth
regulation. Indeed, we have quite recently demonstrated that GM-CSF
is a major paracrine growth factor, expressed in fibroblasts and
regulating keratinocyte growth and differentiation.47
An
autocrine mechanism of tumor cell growth stimulation and enhanced
migration by G-CSF and GM-CSF has been demonstrated in
vitro.41
Furthermore, there is evidence that both
factors modulate the tumor microenvironment by enhancing stromal
activation and inducing angiogenesis in heterotransplants (MM Mueller
and NE Fusenig, manuscript in preparation). Thus, expression of
G-CSF and GM-CSF is a common characteristic associated with the
in vivo progression of HaCaT cells to a highly malignant
phenotype, independently of the H-ras status. By their
autocrine and paracrine functions both newly expressed growth factors
may well contribute to tumor progression.
|
In marked contrast to their drastically increased growth potential in heterotransplants, the tumor-recultivated cell lines did not exhibit improved growth rates in culture. This was evident on the initial adaptation of the outgrowing tumor cells from dissected tumor specimen, where growth initiation in culture required the use of fibroblast feeder cells. Whereas the benign parental A-5 cells showed clonal growth potential in media with low or even no serum content (data not shown), the more malignant tumor cells did not possess a growth advantage under in vitro conditions, and were even less adapted to growing in culture than their parental cells. This was still evident after several passages of culture adaptation, when the metastatic A-5RT3 cells maintained a clearly reduced growth rate (ie, increased population doubling time) in vitro (31 hours) compared to the malignant A-5RT1 (23.6 hours) and benign A-5 cells (20 hours).
Furthermore, when plated at clonal cell densities in media containing 5% FCS, A-5RT1 and A-5RT3 exhibited a reduced colony-forming efficacy compared to A-5 cells, whereas the size of the colonies formed was similar (data not shown). At a density of 100 cells per 6-cm dish colony-forming efficacy of A5 cells was set to 100%, whereas A-5RT1 and A-5RT3 cells only showed a colony-forming efficacy of 57% and 63%, respectively. Under serum-free culture conditions A-5 cells were still able to form 5% colonies, whereas A-RT1 and A-5RT3 cells did not grow at all (data not shown). This reduced growth potential in vitro was maintained throughout many (up to 25) passages in culture.
In Vitro Cloning Does Not Select for a Malignant Phenotype
The chromosomal data indicated that selection of an A-5
subpopulation may be involved in tumor progression to the recultivated
tumor lines. Thus, it might be possible to select for such a
subpopulation by single-cell cloning in vitro. Although
continued passaging of the A-5 cell population did not result in a gain
of the malignant phenotype and the in vitro propagation of
the malignant HaCaT-ras clone II-4 had not increased its malignant
potential (data not shown), we tried to select and isolate a malignant
subpopulation of the A-5 cells. A-5 cells were cloned with ring
isolation and 15 clones were obtained and further propagated. However,
none of these clones formed malignant tumors after subcutaneous
injection (Figure 8A)
. On the contrary,
most of the resulting clones were nontumorigenic and only three gave
rise to persistent benign tumors. Interestingly, two of the subclones
A-5/c and A-5/a formed progressively enlarging tumors in one of eight
and two of eight injection sites, respectively. However, this occurred
only after a long lag period of more than 3 months. Because these A-5
subclones are already the result of single-cell isolations (ie, of
clonal origin), this late tumor progression in vivo suggests
a development of new mutations under the influence of the in
vivo microenvironment. The failure to clone a progressively
malignant subpopulation in vitro was also confirmed by two
sets of experiments attempting to isolate malignant subclones from the
benign HaCaT-ras cell line I-7 and the low-grade malignant line II-4,
respectively (P Tomakidi and NE Fusenig, unpublished observations).
Single cell clones of both cell lines showed no malignant invasive
growth in the short-term tumorigenicity assay of surface transplants
during an observation period of 4 weeks.
|
. Although the
enhanced malignancy of the A-5RT cell lines was in principle maintained
throughout 45 in vitro passages, including their altered
cytology, the in vivo growth rate of malignant tumors was
delayed with increasing number of in vitro passages (Figure 8B
, inset). |
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
In contrast, the in vitro environment did not support tumor progression to a more malignant phenotype. In vitro passage of benign HaCaT-ras clone A-5 and malignant HaCaT-ras clone II-4, did not lead to progressive tumor cell populations (P Tomakidi and NE Fusenig, unpublished observations). Additionally, the benign tumorigenic phenotype of A-5 cells was stably maintained after prolonged passage in vitro up to 72 passages, however, despite its phenotypic stability, we observed a reduction in tumor growth rate after prolonged passage. A similar decrease in tumorigenicity after prolonged in vitro passage was observed with all tumorigenic cell lines tested as well as in a cell line derived from a human skin SCC.54 This difference in selective pressure for tumor progression between the in vitro and the in vivo environment is also reflected in the phenotype of in vivo progressed populations, which exhibit a decreased in vitro growth capacity, as was seen when A-5RT cells were compared to the parental A-5 cells. Although A-5RT cells, to survive in vitro, originally required growth support by feeder fibroblasts that mimic a mesenchymal compartment55 they became independent of these feeder cells during prolonged passages in tissue culture. However, they retained a reduced in vitro growth potential compared to A-5 cells, as is evident from population doubling times and cloning experiments. This discrepancy between in vitro and in vivo growth capacity in our system is not surprising, because even tumor-derived cells of fast growing tumors such as basal cell carcinomas were difficult to propagate in culture.56,57 There are a few examples in the literature describing an in vitro progression to a more malignant phenotype.19,24 However, this in vitro progression either occurred in simian virus-40 immortalized cell lines,19 that are characterized by an increased genetic instability, or required the action of an additional mutagen such as radiation.24 We have found a decrease in tumor progression in vitro for the HaCaT-ras model system and these findings are in agreement with reports demonstrating an in vitro selection against tumorigenic subpopulations in breast adenocarcinomas,58 SCCs arising in Bowen’ disease,59 and prostate carcinomas.60
Tumor progression in vivo is thought to be associated with specific genetic alterations and/or the selection of genetic subpopulations supposedly induced by adverse environmental conditions, eg, hypoxia.61,62 Genetic analyses of our A-5/A-5RT cell progression model supports both mechanisms. The selection of A-5RT cells form a pre-existing subpopulation of the benign A-5 cells was clearly confirmed by the conservation of all A-5 marker chromosomes as well as by the presence of one copy of M1* and M2 in the malignant tumor clones. On the other hand, the detection of novel aberrations, with progression to the malignant phenotype in A-5RT cells, such as the M1RT (add(11)(q23)) and M2RT (del2(p23)) marker chromosomes, points to the acquisition of new genetic rearrangements as a second mechanism active during in vivo tumor progression. The role of chromosomal alterations, and, more specifically, the loss of chromosomal material in tumor progression, is well established.63 Interestingly, the involvement of chromosomes 11 and 2p affects two locations known to harbor a number of genes involved in tumor development, such as the Wilms’ tumor suppressor genes64 and the cyclin D1 gene65 on chromosome 11, or the MSH2 gene66 and the fra-2 gene on 2p,67 respectively. However, further studies are needed to identify the function of these chromosomal aberrations and the role such respective candidate genes may play during tumor progression in our skin carcinoma model system.
In addition to these chromosomal alterations that may result from
mutational events exerted by the in vivo environment,
progression of the A-5 cells was associated with an apparent gene
amplification and with an increased expression of the H-ras
oncogene. However, it remains unclear whether this is the result of the
selection of a pre-existing subpopulation already carrying this
amplification or the consequence of genetic rearrangements induced by
the in vivo environment. The oncogenic activation of
ras has been observed in 
15% of SCCs of the
skin38,39
and shown to contribute to the tumorigenic
conversion of HaCaT skin keratinocytes.10,34
Additionally,
there are other reports associating the dose of ras protein
with malignant conversion or tumor progression.68,69
On
the other hand, several authors have questioned the dominant role of
ras in the process of malignant transformation and tumor
progression.70-72
In the original benign and malignant
HaCaT-ras clones the degree of malignancy did not correlate with the
level of expression of the mutated H-ras
oncogene.34
Additionally, in vivo tumor
progression in the HaCaT system can also occur independently of an
H-ras oncogene activation or overexpression, as demonstrated
for the progression of the HaCaT40° and HaCaTp cells to the more
aggressive HaCaT40°RT and HaCaTpT cells. We therefore consider the
amplification of the H-ras oncogene in the A-5RT cells, to
be a marker for the mutagenic influence of the tumor microenvironment
that might result in a gene amplification of the H-ras
oncogene similar to those seen under stressful growth conditions for
the c-myc oncogene.73
A clear indication for additional genetic alterations causing the phenotypic changes occurring during malignant progression is the novel and constitutive expression of the hematopoietic growth factors G-CSF and GM-CSF that is shared by all highly malignant HaCaT tumor cells arising as a consequence of tumor progression in vivo. Interestingly, despite the possible role that H-ras oncogene activation may play in developing a tumorigenic phenotype in HaCaT cells, this expression of G-CSF and GM-CSF in all highly malignant tumor cells is independent of a H-ras activation. Thus, expression of G-CSF and GM-CSF is a common characteristic associated with the in vivo progression of HaCaT cells to a highly malignant phenotype, independently of the initial H-ras status. In normal skin, G-CSF and GM-CSF are expressed by stromal fibroblasts.74 They can be induced by interleukin-147 and stimulate keratinocyte growth and differentiation. Their novel constitutive expression in the highly malignant HaCaT cells leads to a shift from a paracrine to an autocrine growth regulatory loop without the need for interleukin-1 mediated G-CSF and GM-CSF induction, resulting in the stimulation of tumor cell proliferation and migration, and facilitating tumor invasion and metastasis.41 Comparably, de novo expression of both growth factors has been observed in high-grade malignant gliomas75 and head and neck tumors (MM Mueller, C Herold-Mende, S Ninde, C Reisses, NE Fusenig, manuscript in preparation). Additionally, tumor cell-expressed G-CSF and GM-CSF might act in a paracrine manner on endothelial cells contributing to tumor-induced angiogenesis.41 Therefore, both factors may contribute to the increasingly malignant growth of these cells in vivo.
Thus, the increase in malignancy of the in vivo passaged cells results from their better adaptation to the in vivo growth environment as indicated by their increased capacity to induce stromal activation and tumor angiogenesis. A-5RT cells induce an earlier and stronger activation of the tumor stroma and an enhanced angiogenic response, partly resulting from strong vascular endothelial growth factor expression (S Vosseler, M Skobe, and NE Fusenig, unpublished observations). In vivo selection of more malignant tumor cell populations with a higher metastatic potential has also been reported for prostate carcinomas,49 colon carcinomas,50 transitional cell carcinomas of the bladder,51 and pancreatic carcinomas.52,53 Tumor progression in these systems is also associated with the increased expression of angiogenic growth factors such as vascular endothelial growth factor and basic fibroblast growth factor and other cytokines such as interleukin-8.51,52
Thus, the in vivo growth environment generally seems to exert a characteristic selective pressure resulting in the development of an ever more malignant tumor phenotype, which is frequently associated with alterations in the expression profile of growth factors and cytokines. Recent evidence shows that this tumor progression is not only the result of a malignant conversion of the tumor cells themselves but rather is dependent on a critical contribution of the tumor stroma.76,77 Activation of the stroma by constitutive expression of PDGF in nontumorigenic HaCaT cells promotes their growth as benign tumors.78 Olumi and colleagues79 documented the crucial role of fibroblast from the tumor stroma in determining the malignant phenotype of premalignant prostate cells, however the mechanisms by which the tumor stroma contributes to malignant progression remain primarily unclear. Besides a selective pressure of the stroma that might further the survival of more malignant tumor cells, Yuan and colleagues61,62 discuss fluctuation in hypoxia, low pH, and nutrient deprivation as potential mutational influences of the microenvironment, resulting in secondary modifications of critical proteins involved in replication, repair or cell cycle regulation. In this context the hypoxia-induced expression of interleukin-180 may initially contribute to an activation of G-CSF and GM-CSF expression in the tumor cells that eventually becomes constitutive through the mutational influences that the hypoxic, low pH tumor microenvironment would exert on the tumor cells. However, much work is needed to better understand the mechanisms of tumor progression by selection and mutation via the microenvironment. We conclude that the in vivo progression model of SCCs established in our group, representing distinct and consecutive steps in tumor development and progression, provides an excellent basis to investigate and better understand the complex mechanisms controlling the interaction of tumor cells with their microenvironment and contributing to tumor progression in vivo.
|
Acknowledgements |
|---|
|
Footnotes |
|---|
Supported by the Verein zur Foerderung der Krebsforschung e.V. and DFG SPP "Angiogenesis" (Fu 91-5).
M. M. M. and W. P. both contributed equally to this article.
Accepted for publication July 11, 2001.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. J Cell Physiol 1996, 166:585-592[Medline]
This article has been cited by other articles:
 |
|
 |
|
  P. Geserick, M. Hupe, M. Moulin, W. W.-L. Wong, M. Feoktistova, B. Kellert, H. Gollnick, J. Silke, and M. Leverkus Cellular IAPs inhibit a cryptic CD95-induced cell death by limiting RIP1 kinase recruitment J. Cell Biol., December 28, 2009; 187(7): 1037 - 1054. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Shojaei, X. Wu, X. Qu, M. Kowanetz, L. Yu, M. Tan, Y. G. Meng, and N. Ferrara G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models PNAS, April 21, 2009; 106(16): 6742 - 6747. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Palmowski, J. Huppert, G. Ladewig, P. Hauff, M. Reinhardt, M. M. Mueller, E. C. Woenne, J. W. Jenne, M. Maurer, G. W. Kauffmann, et al. Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects Mol. Cancer Ther., January 1, 2008; 7(1): 101 - 109. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Pivarcsi, A. Muller, A. Hippe, J. Rieker, A. van Lierop, M. Steinhoff, S. Seeliger, R. Kubitza, U. Pippirs, S. Meller, et al. Tumor immune escape by the loss of homeostatic chemokine expression PNAS, November 27, 2007; 104(48): 19055 - 19060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Willhauck, N. Mirancea, S. Vosseler, A. Pavesio, P. Boukamp, M. M. Mueller, N. E. Fusenig, and H.-J. Stark Reversion of tumor phenotype in surface transplants of skin SCC cells by scaffold-induced stroma modulation Carcinogenesis, March 1, 2007; 28(3): 595 - 610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Zhang, M. Jugold, E. C. Woenne, T. Lammers, B. Morgenstern, M. M. Mueller, H. Zentgraf, M. Bock, M. Eisenhut, W. Semmler, et al. Specific Targeting of Tumor Angiogenesis by RGD-Conjugated Ultrasmall Superparamagnetic Iron Oxide Particles Using a Clinical 1.5-T Magnetic Resonance Scanner Cancer Res., February 15, 2007; 67(4): 1555 - 1562. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. E. Oki-Idouchi and P. S. Lorenzo Transgenic Overexpression of RasGRP1 in Mouse Epidermis Results in Spontaneous Tumors of the Skin Cancer Res., January 1, 2007; 67(1): 276 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Nishimura, K. Itoh, K. Ito, M. Yanada, K. Terauchi, S. Fushiki, and J. Shimada Autocrine Growth by Granulocyte Colony-Stimulating Factor in Malignant Mesothelioma Ann. Thorac. Surg., November 1, 2006; 82(5): 1904 - 1906. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Gutschalk, C. C. Herold-Mende, N. E. Fusenig, and M. M. Mueller Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor Promote Malignant Growth of Cells from Head and Neck Squamous Cell Carcinomas In vivo Cancer Res., August 15, 2006; 66(16): 8026 - 8036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Aziz, D. L. Wheeler, B. Bhamb, and A. K. Verma Protein Kinase C {delta} Overexpressing Transgenic Mice Are Resistant to Chemically but not to UV Radiation-Induced Development of Squamous Cell Carcinomas: A Possible Link to Specific Cytokines and Cyclooxygenase-2 Cancer Res., January 15, 2006; 66(2): 713 - 722. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Miller, S. Vosseler, N. Mirancea, D. J. Hicklin, P. Bohlen, H. E. Volcker, F. G. Holz, and N. E. Fusenig Rapid Vessel Regression, Protease Inhibition, and Stromal Normalization upon Short-Term Vascular Endothelial Growth Factor Receptor 2 Inhibition in Skin Carcinoma Heterotransplants Am. J. Pathol., November 1, 2005; 167(5): 1389 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Boukamp Non-melanoma skin cancer: what drives tumor development and progression? Carcinogenesis, October 1, 2005; 26(10): 1657 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Nagai, H. Miyazawa, Huqun, T. Tanaka, K. Udagawa, M. Kato, S. Fukuyama, A. Yokote, K. Kobayashi, M. Kanazawa, et al. Genetic Heterogeneity of the Epidermal Growth Factor Receptor in Non-Small Cell Lung Cancer Cell Lines Revealed by a Rapid and Sensitive Detection System, the Peptide Nucleic Acid-Locked Nucleic Acid PCR Clamp Cancer Res., August 15, 2005; 65(16): 7276 - 7282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Vosseler, N. Mirancea, P. Bohlen, M. M. Mueller, and N. E. Fusenig Angiogenesis Inhibition by Vascular Endothelial Growth Factor Receptor-2 Blockade Reduces Stromal Matrix Metalloproteinase Expression, Normalizes Stromal Tissue, and Reverts Epithelial Tumor Phenotype in Surface Heterotransplants Cancer Res., February 15, 2005; 65(4): 1294 - 1305. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Sreeramaneni, A. Chaudhry, M. McMahon, C. J. Sherr, and K. Inoue Ras-Raf-Arf Signaling Critically Depends on the Dmp1 Transcription Factor Mol. Cell. Biol., January 1, 2005; 25(1): 220 - 232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Obermueller, S. Vosseler, N. E. Fusenig, and M. M. Mueller Cooperative Autocrine and Paracrine Functions of Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor in the Progression of Skin Carcinoma Cells Cancer Res., November 1, 2004; 64(21): 7801 - 7812. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Krix, F. Kiessling, S. Vosseler, N. Farhan, M. M. Mueller, P. Bohlen, N. E. Fusenig, and S. Delorme Sensitive Noninvasive Monitoring of Tumor Perfusion during Antiangiogenic Therapy by Intermittent Bolus-Contrast Power Doppler Sonography Cancer Res., December 1, 2003; 63(23): 8264 - 8270. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
X174/HaeIII digest).
Fibroblasts and enhanced malignant HaCaT cells, HaCaTpT and
HaCaT40°RT, as well as HaCaT-ras cells A-5RT1, A-5RT3, and II-4RT
expressed G-CSF and GM-CSF mRNA, whereas benign A-5, HaCaTp, and
HaCaT40°, and malignant II-4 cells did not.